GGrantIndex
Sort

40,608 grants matching prostate cancer

An Immune Based Therapeutic Approach for Prostate Cancer

$352,615
Esteban Celis · Mayo Clinic Rochester · P50 · FY2010 · CA

Ack1: A Critical Regulator of Hormone-Refractory Prostate Cancer

$352,581
Nupam P Mahajan · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2010 · CA

Project 1: Resistance caused by AR pathway reactivation

$352,577
Charles L Sawyers · Sloan-Kettering Inst Can Research · U54 · FY2020 · CA

Core B - Animal Core

$352,446
Evan Todd Keller · University Of Michigan At Ann Arbor · P01 · FY2023 · CA

Investigation of the landscape of immunosequencing and its clinical relevance through novel immunoinformatic approaches

$352,441
Li Zhang · University Of California, San Francisco · R01 · FY2022 · LM

Defining the role of isoprenylated xanthones from the mangosteen for enhancing degradation of full length and variant forms of androgen receptor in prostate cancer

$352,420
Jeremy James Johnson · University Of Illinois At Chicago · R37 · FY2020 · CA

Defining the role of isoprenylated xanthones from the mangosteen for enhancing degradation of full length and variant forms of androgen receptor in prostate cancer

$352,420
Jeremy James Johnson · University Of Illinois At Chicago · R37 · FY2019 · CA

Role of histone demethylase JMJD1A in the DNA damage response of prostate cancer cells

$352,371
Jianfei Qi · University Of Maryland Baltimore · R01 · FY2016 · CA

CYCLIN D1 FUNCTION IN PROSTATE CANCER

$352,361
Yeshiva University · R01 · FY2001 · CA

Project 2 - Fatty Liver Predisposes to Metastasis: Role of Hepatic Stellate Cells

$352,342
Ekihiro Seki · Cedars-Sinai Medical Center · P01 · FY2020 · CA

Elucidating the Role of Trop2 in Prostate Cancer

$352,304
Tanya I Stoyanova · University Of California Los Angeles · R37 · FY2023 · CA

Self-assembling protoviral nanoparticles

$352,293
Nadya Tarasova · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA

Identify the Mechanisms of LMO2-Mediated Inhibition of Homologous Recombination and Establish PARP-Targeted Synthetic Lethality as a New Therapy for DLBCL

$352,286
Izidore S Lossos · University Of Miami School Of Medicine · R01 · FY2023 · CA

Identify the Mechanisms of LMO2-Mediated Inhibition of Homologous Recombination and Establish PARP-Targeted Synthetic Lethality as a New Therapy for DLBCL

$352,283
Izidore S Lossos · University Of Miami School Of Medicine · R01 · FY2022 · CA

Radiotherapy-induced tumor immunity

$352,275
Dorthe Schaue · University Of California Los Angeles · R01 · FY2017 · CA

Adaptive resistance to AR inhibitors in hypoxia by GPT1

$352,275
Zheng David Qian · Oregon Health & Science University · R01 · FY2023 · CA

Radiotherapy-induced tumor immunity

$352,275
Dorthe Schaue · University Of California Los Angeles · R01 · FY2015 · CA

Radiotherapy-induced tumor immunity

$352,275
Dorthe Schaue · University Of California Los Angeles · R01 · FY2016 · CA

Pathobiology and Mechanism of Progesterone Resistance in Human Endometrial Cancer

$352,275
Sanaz Memarzadeh · University Of California Los Angeles · R01 · FY2016 · CA

Prospective Assessment of Image Registration for the Diagnosis of Prostate Cancer

$352,275
Leonard Stephen Marks · University Of California Los Angeles · R01 · FY2016 · CA

Radiotherapy-induced tumor immunity

$352,275
Dorthe Schaue · University Of California Los Angeles · R01 · FY2018 · CA

Prospective Assessment of Image Registration for the Diagnosis of Prostate Cancer

$352,275
Leonard Stephen Marks · University Of California Los Angeles · R01 · FY2015 · CA

Pathobiology and Mechanism of Progesterone Resistance in Human Endometrial Cancer

$352,275
Sanaz Memarzadeh · University Of California Los Angeles · R01 · FY2017 · CA

Pathobiology and Mechanism of Progesterone Resistance in Human Endometrial Cancer

$352,275
Sanaz Memarzadeh · University Of California Los Angeles · R01 · FY2015 · CA

Adaptive resistance to HIF1a inhibition in hypoxia

$352,242
Zheng David Qian · Oregon Health & Science University · R01 · FY2016 · CA